Introduction
First recorded by Vieusseaux in 1805, 1 meningococcal disease is a worldwide public health problem and, when associated with purpura fulminans and haemodynamic deterioration, mortality rates of 20-30% have been recorded. 2, 3 In those patients who survive the acute phase of the severe illness, mutilating complications and end-organ failure are common. 4, 5 Hyperendemic invasive meningococcal disease (IMD) in Ireland, which currently has the highest incidence of laboratory-confirmed disease in Europe, 6 continues to cause concern as a result of the unpredictability of the disease.
The pathophysiology of severe meningococcaemia is becoming increasingly clear. Meningococcal endotoxin, LPS, is now understood to be crucial in the pathogenesis of the disease. This microbial constituent, in a dosedependent manner, activates the haemostatic cascades of procoagulation, anticoagulation, fibrinolysis, and the complement and kallikrein/kinin systems, together with inflammatory mediator systems such as the cytokine network. The net procoagulant effect and the generation of proinflammatory cytokines result in widespread microvascular thrombosis with tissue toxicity and injury.
Key cytokines participating in the regulation of the inflammatory response include proinflammatory IL-1, IL-6, and TNF, and anti-inflammatory IL-10 and IL-1 receptor antagonist (IL-1Ra). IL-6, a multifunctional cytokine with both proinflammatory properties and procoagulant effects, is involved in regulation of both the immune response and haematopoiesis. 7 High circulating plasma levels of IL-6 have been associated with poor outcome in patients with meningococcal shock, 8, 9 sepsis, 10, 11 melioidosis, 12 and in neonatal sepsis and other neonatal septic conditions. 13 TNF-a is widely reported to be a pivotal mediator of sepsis, septic shock, and multiple organ failure, and high circulating plasma levels of TNF-a have been found to correlate with poor outcome in patients with meningococcal shock 8, 14, 15 and in patients with other forms of sepsis. 16, 17 IL-1b, an agonist, is a potent proinflammatory cytokine, 18 whereas IL-1Ra, an antagonist, inhibits the activities of IL-1b by binding to the IL-1 receptor and blocking signal transduction. 19, 20 As with TNF-a and IL-6, levels of IL-1b are associated with the outcome in meningococcal disease. 8, 9, 17 IL-10, an important suppressor of the inflammatory response, downregulates endotoxin-stimulated monocyte synthesis of proinflammatory cytokines such as IL-1, TNF-a, IL-6, IL-8, and IL-12, and upregulates the synthesis of IL-1Ra. 21, 22 A number of cytokine gene polymorphisms have been described in association with altered constitutive and inducible levels of cytokines, 23 and this provides a rationale for their potential role in meningococcal disease severity. Although there is some conflicting evidence for the functionality of these polymorphisms, we postulated that polymorphisms which influence variations in cytokine levels could have an effect on the inflammatory response to invasive infection with Neisseria meningitidis. Given the observations that plasma levels of the proinflammatory cytokines IL-1b, TNF-a, and IL-6 are elevated in this disease, and that higher levels directly correlate with increased severity and fatality, we wished to investigate whether polymorphism status in pro-and anti-inflammatory genes is associated with disease severity and outcome in meningococcal septic shock. We therefore studied the genotype frequencies of seven such polymorphisms in a group of patients with meningococcal disease and a control population, in order to determine if any polymorphism is associated with disease susceptibility, severity, or outcome.
Results

Control and patient groups
In all, 193 samples from patients with IMD were collected (110 mild, 83 severe). Group B meningococcus accounted for 78% of infections and group C for the remainder. The characteristics of patients with IMD presenting to one of two paediatric hospitals and on whom clinical details were available prior to unlinking samples are shown in Table 1 . Clinical details were unavailable for 22 patients (11%) who died in other hospitals. For all the seven cytokine polymorphisms, 389 control samples and 183 IMD patient samples were genotyped. For analysis, the IMD group was divided into mild disease (n¼107) and severe disease (n¼76) groups. For further analysis, this group was also divided into survivor (n¼158) and nonsurvivor (n¼25) groups. Therefore, three separate comparisons were made in this study. Firstly, the IMD group was compared to the control group for each of the seven polymorphisms. The second comparison was made between the mild and severe disease groups, while the final comparison was between the survivor and nonsurvivor groups for each polymorphism.
IL-6 G-174C polymorphism
Raw data, genotype frequencies, and allele frequencies obtained for this polymorphism in the control and IMD populations are listed in Table 2 
IL-1RN VNTR
Frequencies of IL-1RN genotypes in the IMD population and in the control population are shown in Table 3 . For the IL-1RN VNTR, the only statistically significant finding among the groups of disease severity was found to occur in the fatal group, where the frequency of the 1/2 genotype was significantly lower (20 vs 37-41%, Tachycardia, capillary refill X3 s, and administration of 410 ml/kg fluid bolus in the emergency room, with or without hypotension.
P¼0.0433), and 1/1 higher, than in any of the other groups. The frequency of the 2/2 genotype, which has been associated with higher IL-1Ra levels, was significantly lower in the control group compared to the IMD group (P¼0.0326).
IL-1B þ 3953, IL-10 À592, LTA þ 252, and TNF À308 Genotype and allele frequencies were not significantly different among the groups of disease severity for these polymorphisms, or when comparing the disease and control groups (Table 3) , despite some variation in genotype frequencies among disease groups.
Multipolymorphism analysis: IL-6 À174, IL-10 À1082, IL-1RN VNTR Details of analysis of combinations of genotypes are shown in Table 4 . Combinations of genotypes identified as potentially associated with IMD severity and survival by univariate analysis (IL-6 À174 G/G, IL-10 À1082 A/A, and IL-1RN 1/1) were investigated. Higher frequencies of individuals carrying combinations of high-risk genotypes were seen in the severe disease group compared to the mild group, and in the nonsurvivor group compared to the survivor group, although not all had significant w 2 P-values (Table 4 ). In Table 2 Raw data, genotype or allele frequencies (in parentheses), and w 2 P-values for the IL-6 À174 and IL-10 À1082 polymorphisms in patients with meningococcal disease and in a control population; The patient group is further divided into groups of disease severity, and groups of survivors and nonsurvivors order to assess the simultaneous presence of all the three risk variants, nominal logistic regression was used to test the combined effect of carriage of the IL-6 À174 G/G, IL-10 À1082 A/A, and IL-1RN 1/1 genotypes together. For mild vs severe disease, it was found that these three factors are not significantly associated with disease severity (P¼0.08). The same analysis looking at survival found these three factors to have even less of an influence (P¼0.11). Testing the effect of carriage of two genotypes, significant P-values were obtained for IL-6 À174 G/G with IL-10 À1084 A/A for mild vs severe disease, and for the IL-1RN VNTR 1/1 genotype with both the IL-6 À174 G/G and the IL-10 À1082 A/A genotypes for survival, although the IL-1RN 1/1 and IL-6 G/G combination was more significant (w 2 P¼0.0008) ( Table 4) .
Discussion
Meningococcal disease severity varies widely, from bacteraemia, through meningitis, to overwhelming septicaemia, although it is unclear why some patients develop mild manifestations of invasive meningococcal infection, while on the other end of the spectrum some individuals rapidly develop fulminant septicaemia characterised by extensive microvascular thrombosis, consumptive coagulopathy, multiorgan dysfunction, and a high risk of mortality and mutilating complications, particularly in those patients who develop septic shock. Meningococcal septicaemia results from the release of bacterial endotoxin into the bloodstream, with the subsequent activation of systemic inflammation and coagulation cascades, and inhibition of fibrinolysis. Many of the sequelae associated with endotoxaemicinduced shock result from excessive production of the cytokine mediators TNF-a, IL-1b, and IL-6 from lipopolysaccharide-activated monocytes. Genomic polymorphisms within the genes encoding these endogenous mediators may affect the extent of an individual's primary (TNF-a and IL-1b) and secondary (IL-6) inflammatory responses, and hence could contribute to morbidity and mortality patterns in patients with severe sepsis. We therefore genotyped a population of patients with meningococcal disease, and a large control population for polymorphisms in seven cytokine genes, in order to determine if certain genotypes are associated with disease susceptibility, severity, or survival.
The IL-6 À174 G allele has been previously associated with increased IL-6 levels, [24] [25] [26] although the association may be age-and sex-related, 27, 28 and no association between this polymorphism and IL-6 levels has also been reported. 29 We found an association between homozygous carriage of the IL-6 À174 G allele and poor outcome in meningococcal disease. Higher IL-6 levels have been found to be strongly associated with mortality in meningococcal sepsis, 8, 9 and other forms of sepsis. 11, 12 No significant difference in the frequency of genotypes or alleles was found between the group with meningococcal disease and the control population. These findings suggest that while the IL-6 À174 G allele does not increase the risk of an individual acquiring invasive meningococcal infection, its presence will, however, have some influence on whether or not the individual develops severe disease and multiple organ dysfunction during the systemic inflammatory response to N. meningitides.
Meningococcal septicaemia is associated with a proinflammatory state, and IL-10 is believed to play an important role in regulating any such response. The finding that the A/A genotype of the IL-10 À1082 polymorphism is at a significantly higher frequency in the severe meningococcal disease group compared to the other groups of disease severity associates a genotype that has been linked to lower levels of the antiinflammatory cytokine IL-10 30 with more severe disease. This observation correlates with the IL-6 polymorphism finding, and the net result relates both a genotype thought to be associated with higher levels of a proinflammatory cytokine (IL-6 À174 G/G) and one associated with lower levels of an anti-inflammatory cytokine (IL-10 À1082 A/A), an overall proinflammatory profile, to more severe meningococcal disease. The nonsurvivors group was not significantly associated with the IL-10 À1082 genotype, despite increased levels of the IL-10 À1082 A/A genotype, which could be due to the relatively small size of this group (n¼25). Although not statistically significant, the IL-10 À592 polymorphism had varying genotype frequencies, especially between the mild and severe disease groups, which could be due Table 4 Raw data, frequencies (in parentheses), and P-values for the carriage of combinations of the IL-6 À174 G/G, IL-10 À1082 A/A, and to linkage with the IL-10 À1082 polymorphism, since the two polymorphisms are located in close proximity in the IL-10 gene. Production of IL-1b, along with TNF-a, is stimulated by bacterial toxins or inflammation early in the acute phase response, causing the subsequent expression of a variety of cytokine and transcription factor genes. In this study, no association was found between the IL-1B þ 3953 polymorphism and meningococcal disease. The balance between IL-1b and IL-1Ra is of importance in normal and disease states, as the margin between beneficial levels of IL-1b and toxicity is very narrow in humans. Despite the expectation that a low IL-1Ra plasma concentration might aggravate the morbidity of sepsis by allowing increased proinflammatory activity to occur, it appears that a coordinated and balanced IL-1/IL-1Ra ratio in the circulation is more important in the course of systemic inflammatory challenges than an overall pro-or anti-inflammatory response, as seen by recombinant IL-1Ra therapy clinical trial results, 31 and the effects of IL-1Ra on mouse and rat sepsis models. 32, 33 Allele 2 of the IL-1RN VNTR, linked to increased levels of IL-1Ra, and thus increased anti-inflammatory activity, 34 has been associated with susceptibility to sepsis. 35 Our finding of a significantly lower level of the 2/2 genotype in controls compared to the meningococcal group as a whole correlates with this study. In contrast, our study also detected a lower frequency of the 1/2 genotype, and a higher frequency of the 1/1 genotype, in the group of patients that died from meningococcal disease compared to those that survived, indicating that homozygous carriage of allele 1 may predispose a poor outcome in meningococcal disease.
As the purpose of this study is to characterise a genetic risk profile for IMD, the simultaneous presence of the identified risk variants in all individuals was assessed. Although carriers of all three risk factors thus far identified, IL-6 À174 G/G, IL-10 À1082 A/A, and IL-1RN VNTR 1/1, were more common in the severe or nonsurvivor groups compared to mild or survivor groups (Table 4) , these associations were not notably more significant than when looking at the risk factors alone. Nominal logistic regression analysis of the carriage of two higher risk genotypes revealed a significant association for the carriage of IL-6 À174 G/G and IL-10 À1082 A/A when comparing mild to severe disease; and for carriage of the IL-6 À174 G/G and IL-1RN VNTR 1/1 when comparing survivors to nonsurvivors (Table 4) . However, despite the significant associations obtained from multivariate analysis, the fact that this analysis did not show greatly increased significance compared to univariate analysis leads to the conclusion that these three factors are associated with IMD severity and survival independently of each other, and that IMD patients carrying all the three genotypes are not at a significantly greater risk of more severe IMD or death than those carrying just one of these factors alone.
Both the TNF À308 and LTA þ 252 polymorphisms have been associated with variations in TNF-a levels, [36] [37] [38] and may therefore have an effect on IMD severity and outcome. However, we found no association between alleles of either the TNF À308 or LTA þ 252 polymorphisms and disease outcome or severity. This contrasts with studies linking severe sepsis outcome and LTA þ 252 genotype, 36, 37 and the TNF À308 polymorphism with outcome in septic shock and meningococcal disease. 39, 40 However, our findings concur with those of another study in which it was reported that there is no association between the TNF À308 polymorphism and severe sepsis. 41 The discrepancy between the findings in these different studies could be a result of differing disease severity scoring methods, differing lengths of time before hospitalisation and treatment, and variations in the rapidity and type of treatment, all factors that may vary in different geographical areas. Differing diseasecausative organisms, possibly causing slightly different inflammatory responses, and the gender makeup of the study population are other factors that could affect the association between genotype and outcome. 42 Our study had some limitations and potential sources of bias. Some patients who died presented to other centres and clinical data were unavailable. The retrospective study design and the requirement of the Ethics Committee that all samples be completely and irreversibly unlinked from all patient details prior to analysis rendered us unable to analyse polymorphism associations with factors such as age and gender. This study should therefore be viewed as a preliminary exploratory study. It must be noted that the associations found, although statistically significant, were not highly so, and further investigations are required in this area. Thus, the presence of the IL-6 À174 G/G and IL-10 À1082 A/A genotypes, along with the IL-1RN VNTR association noted in this study, are likely to be only a part of the genomic polymorphic risk profile for severe meningococcal sepsis. Genes encoding proteins outside the cytokine network but closely linked with the systemic inflammatory response, such as those involved in procoagulation, anticoagulation, fibrinolysis, complement, and kallikrein/kinin systems, are potential candidates for further study.
Why some individuals develop a more severe form of meningococcaemia is not fully understood but is undoubtedly multifactorial, and we believe, as in other forms of sepsis, that no single cause and effect paradigm exists. We do know that there is a strong correlation between the severity of the acquired protein C deficiency that may be seen in this disease, the extent of the thrombotic skin lesions, and a negative clinical outcome. 43 Likewise, it is now understood that certain genetic determinants of an individual's systemic inflammatory response may also influence the outcome in these patients. The finding of the present study that polymorphisms in the IL-6, IL-10, and IL-1RN genes are associated with disease outcome in meningococcaemia will hopefully generate further insights into the pathophysiology of sepsis, which will encourage future clinical investigations into different biological interventions that will ultimately lead to the availability of effective antisepsis therapies.
Patients and methods
Controls
The control population consisted of 389 Caucasian Irish blood donors (male 58% : female 42%, mean age 37.1, range 18-65 years), obtained from the Northern Ireland Blood Transfusion Service (n¼60) and the Irish Blood Transfusion Service (n¼329).
Patients with IMD
The Irish Meningococcal and Meningitis Reference Laboratory (IMMRL) at The Children's University Hospital, Temple Street, Dublin, provides a national service for nonculture diagnosis of IMD by polymerase chain reaction (PCR) analysis for the citrA gene (specific to N. meningitidis) in blood, cerebrospinal fluid, and samples from other sterile sites. Residual bloods from samples taken for routine PCR are stored in the IMMRL at À701C. Ethical approval for this study using residual blood samples submitted for PCR from patients in the IMMRL database was obtained from The Children's University Hospital, on condition that all samples be irreversibly unlinked from all patient identifiers and clinical details prior to analysis.
The study cohort was derived from two sources: children identified from the database between January 1997 and February 2000, who presented to one of two tertiary referral paediatric hospitals in Dublin (The Children's University Hospital, Temple Street, and Our Lady's Hospital for Sick Children, Crumlin), and, secondly, patients on the database known to have died in other hospitals, and on whom such samples were available. The medical records of study children were reviewed and clinical and laboratory data collected retrospectively, with patient identification details known to only one investigator, prior to unlinking samples. Meningococcal disease treatment protocols were similar in both hospitals. Complete data required for a Glasgow Meningococcal Sepsis Prognostic Score (GMSPS), or PRISM score, were not available on all patients. A scoring system based on prognostic factors independently demonstrated as being predictive of severe illness and poor outcome in IMD, for which complete data were available on all children, was designed.
3,44-64 Additional therapies (eg ventilation, inotropes, protein C, haemofiltration) and clinical indicators of severity of illness (eg prolonged intensive care unit (ICU) stay or fever) were also included for scoring purposes. An independent verification of the scoring system was obtained from paediatricians not involved in this study, who are experienced in the care of children with IMD.
Patients were divided into two groups for statistical analysis. The first analysis involved dividing the cohort into two groups based on clinical severity of disease. Group 1 comprised patients with mild illness who recovered without sequelae. Group 2 comprised those with many poor prognostic factors, survivors with permanent sequelae (permanent scarring, neurological deficit, sensorineural hearing loss, renal failure, amputation), and all deaths. In order to determine whether the presence of a particular polymorphism was associated with mortality, the total population (n¼183) was then divided into those who survived (n¼158) and those who had fatal infection (nonsurvivors, n¼25).
Nucleic acid extraction DNA was isolated from the EDTA-anticoagulated control bloods using a rapid large-volume extraction protocol. Briefly, whole blood was washed three times in 10 mM NaCl, 10 mM EDTA (pH 7.0), pelleted, and resuspended in 1.25 ml of 200 mM NaOH. Following incubation at 971C for 15 min, the sample was neutralised with an equivalent volume of 200 mM HCl, 100 mM Tris-HCl (pH 8.5). DNA was isolated from the meningococcal sepsis blood samples using the Puregene extraction procedure (Gentra Systems, Minneapolis, USA) according to the manufacturer's instructions.
PCR and RFLP assays
The standard PCR reaction mix consisted of Taq DNA polymerase buffer with MgCl 2 (Promega), 0.4 U of DNA Taq polymerase, 2 ml of genomic DNA, 4% DMSO, 30 mM each of dNTPs, and 0.2 mM each of sense and antisense primer ( Table 5 ). Parameters of each PCR assay, changes to the standard PCR reaction mix, and restriction Each PCR run required 40 cycles; primers were designed and cycling parameters were optimised for the purposes of this study unless otherwise noted; F, forward primer; R, reverse primer; s, seconds; N/A, not applicable.
Cytokine polymorphisms in meningococcal disease J Balding et al enzymes used are listed in Table 5 . PCR or restriction digest products were run in the appropriate percentage of agarose gel (Table 5) containing ethidium bromide, and visualised in UV light.
Statistical analysis
Allele and genotype frequencies were compared between patient and control groups, and between patient subpopulations, by means of the w 2 -test and Fisher's exact test, when appropriate. A w 2 P-value of o0.05 was considered statistically significant. In an exploratory candidate gene study such as this, P-values were not adjusted for multiple comparisons, as it was felt that careful interpretation of any P-values is necessary, and sufficient detail is provided for the readers to make their own adjustment. Odds ratios and the corresponding 95% CI were estimated by cross-tabulation. Nominal logistic regression analysis was performed to assess the influence of multiple polymorphisms on meningococcal disease outcome. Statistics were performed using JMP software (JMP version 4.0.4, SAS Institute Inc., Cary, NC, USA).
